截至9月30日，和邦生物股东户数19.65万，较上期减少1.99%；人均流通股44939股，较上期增加 2.03%。2025年1月-9月，和邦生物实现营业收入59.27亿元，同比减少13.02%；归母净利润9310.85万 元，同比减少57.93%。 分红方面，和邦生物A股上市后累计派现12.05亿元。近三年，累计派现5.53亿元。 机构持仓方面，截止2025年9月30日，和邦生物十大流通股东中，鹏华中证细分化工产业主题ETF联接A （014942）位居第四大流通股东，持股9278.78万股，为新进股东。南方中证500ETF（510500）位居第 五大流通股东，持股9008.99万股，相比上期减少218.44万股。香港中央结算有限公司位居第六大流通股 东，持股8928.26万股，相比上期增加1609.08万股。光大保德信信用添益债券A类（360013）位居第九 大流通股东，持股3300.96万股，为新进股东。中欧红利优享灵活配置混合A（004814）位居第十大流通 股东，持股2459.99万股，为新进股东。 责任编辑：小浪快报 1月9日，和邦生物涨0.00%，成交额3.55亿元。两融数据显示，当日和邦生物获融 ...

分红方面，苏利股份A股上市后累计派现5.85亿元。近三年，累计派现1.08亿元。 资料显示，江苏苏利精细化工股份有限公司位于江苏省江阴市临港街道润华路7号-1，成立日期1994年 12月22日，上市日期2016年12月14日，公司主营业务涉及农药、阻燃剂及其他精细化工产品的研发、生 产和销售。主营业务收入构成为：农药及农药中间体59.86%，阻燃剂及中间体30.84%，其他精细化工 产品8.19%，其他(补充)1.11%。 苏利股份所属申万行业为：基础化工-农化制品-农药。所属概念板块包括：生物农药、小盘等。 截至9月30日，苏利股份股东户数1.21万，较上期减少16.74%；人均流通股15101股，较上期增加 20.11%。2025年1月-9月，苏利股份实现营业收入20.64亿元，同比增长25.39%；归母净利润1.39亿元， 同比增长1522.38%。 1月5日，苏利股份盘中上涨2.01%，截至09:53，报19.24元/股，成交2628.29万元，换手率0.75%，总市 值35.96亿元。 资金流向方面，主力资金净流入39.23万元，大单买入360.48万元，占比13.72%，卖出321.26万元，占比 ...

Core Viewpoint - The stock of Hebang Biotechnology has shown a positive trend with a year-to-date increase of 12.75%, reflecting strong market interest and trading activity [1][2]. Company Overview - Hebang Biotechnology, established on August 1, 2002, and listed on July 31, 2012, is located in Leshan, Sichuan Province. The company specializes in the manufacturing of pesticides, fine chemicals, intelligent glass, special glass, and the development of salt and phosphate mines [2]. - The revenue composition of Hebang Biotechnology includes 85.89% from chemical products, 17.61% from photovoltaic glass and other products, 6.74% from mineral products, and 5.02% from other businesses [2]. Financial Performance - For the period from January to September 2025, Hebang Biotechnology reported a revenue of 5.927 billion yuan, a year-on-year decrease of 13.02%. The net profit attributable to shareholders was 93.11 million yuan, down 57.93% year-on-year [2]. - The company has distributed a total of 1.205 billion yuan in dividends since its A-share listing, with 553 million yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Hebang Biotechnology was 196,500, a decrease of 1.99% from the previous period. The average number of circulating shares per shareholder increased by 2.03% to 44,939 shares [2]. - Notable institutional shareholders include Penghua CSI Sub-Industry Chemical Theme ETF, which is the fourth largest shareholder with 92.79 million shares, and Southern CSI 500 ETF, which is the fifth largest with 90.09 million shares, having decreased its holdings by 2.18 million shares [3].

Core Viewpoint - The stock of Hebang Biotechnology has experienced fluctuations, with a recent decline of 2.35% and a total market capitalization of 18.369 billion yuan, indicating potential volatility in the company's stock performance [1]. Financial Performance - For the period from January to September 2025, Hebang Biotechnology reported a revenue of 5.927 billion yuan, representing a year-on-year decrease of 13.02%. The net profit attributable to shareholders was 931.085 million yuan, down 57.93% compared to the previous year [2]. - The company's stock price has increased by 1.96% year-to-date, but it has seen a significant decline of 14.75% over the last five trading days [1]. Shareholder Information - As of September 30, 2025, the number of shareholders for Hebang Biotechnology was 196,500, a decrease of 1.99% from the previous period. The average number of circulating shares per shareholder increased by 2.03% to 44,939 shares [2]. - The company has distributed a total of 1.205 billion yuan in dividends since its A-share listing, with 553 million yuan distributed over the last three years [3]. Major Shareholders - The fourth largest circulating shareholder is Penghua CSI Sub-Industry Chemical Theme ETF Link A, holding 92.788 million shares as a new shareholder. The fifth largest is Southern CSI 500 ETF, holding 90.090 million shares, which has decreased by 2.1844 million shares from the previous period [3]. - Hong Kong Central Clearing Limited is the sixth largest circulating shareholder, holding 89.2826 million shares, which has increased by 1.60908 million shares compared to the previous period [3].

Group 1 - On November 20, Hebang Biotechnology experienced a decline of 0.86% with a transaction volume of 587 million yuan, and the net financing buy was -4.80 million yuan [1] - As of November 20, the total margin balance for Hebang Biotechnology was 596 million yuan, with the financing balance accounting for 2.88% of the circulating market value, indicating a high level compared to the past year [1] - The company repaid 586,500 shares of margin on November 20, while 847,300 shares were sold short, resulting in a short selling amount of 1.96 million yuan [1] Group 2 - As of September 30, the number of shareholders for Hebang Biotechnology was 196,500, a decrease of 1.99%, while the average circulating shares per person increased by 2.03% to 44,939 shares [2] - For the period from January to September 2025, Hebang Biotechnology reported a revenue of 5.93 billion yuan, a year-on-year decrease of 13.02%, and a net profit attributable to shareholders of 93.11 million yuan, down 57.93% year-on-year [2] Group 3 - Since its A-share listing, Hebang Biotechnology has distributed a total of 1.205 billion yuan in dividends, with 553 million yuan distributed in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders included new entrants such as Penghua CSI Sub-Segment Chemical Industry Theme ETF and Everbright Prudential Credit Bond A, indicating changes in institutional holdings [3]

Group 1 - The core point of the article is that *ST Huifeng held a temporary board meeting on November 16, 2025, to discuss the cancellation of the supervisory board and amendments to the company's articles of association [1] - For the first half of 2025, *ST Huifeng's revenue composition was as follows: pesticides and pesticide intermediates accounted for 57.75%, oil products and bulk chemical storage, transportation, and trade accounted for 34.64%, grain seed sales accounted for 3.85%, and other industries accounted for 3.76% [1] - As of the report date, *ST Huifeng's market capitalization was 2.8 billion yuan [2]

2025 年第三季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上市公司行业信息披露指引第十三号-化工》的要求， 江苏苏利精细化工股份有限公司（以下简称"公司"）现将 2025 年第三季度（1-9 月）主要经营数据披露如下： 一、主要产品的产量、销量及收入实现情况 | 主要产品 | 产量 | 销量 | 营业收入 | | --- | --- | --- | --- | | | （吨） | （吨） | （万元） | | 农药及农药中间体 | 37,569.33 | 37,187.46 | 131,643.84 | | 阻燃剂及阻燃剂中 间体 | 16,205.02 | 15,395.19 | 56,186.61 | | 证券代码：603585 | 证券简称：苏利股份 | 公告编号：2025-078 | | --- | --- | --- | | 转债代码：113640 | 转债简称：苏利转债 | | 江苏苏利精细化工股份有限公司 1 | 4,6-二氯嘧啶 | 6.95 | 7.63 ...

Core Viewpoint - The stock of Hebang Biotechnology experienced a decline of 1.85% on October 20, with a trading volume of 423 million yuan, indicating a challenging market environment for the company [1]. Financing Summary - On October 20, Hebang Biotechnology had a financing buy-in amount of 34.09 million yuan and a financing repayment of 40.44 million yuan, resulting in a net financing outflow of 6.35 million yuan [1]. - The total financing and securities balance for Hebang Biotechnology as of October 20 is 560 million yuan, with the current financing balance of 552 million yuan accounting for 2.95% of the circulating market value, which is below the 40th percentile level over the past year, indicating a low financing level [1]. - In terms of securities lending, on October 20, Hebang Biotechnology repaid 510,700 shares and sold 53,100 shares, with a selling amount of 112,600 yuan based on the closing price of the day. The remaining securities lending volume is 3.94 million shares, with a balance of 8.36 million yuan, which exceeds the 90th percentile level over the past year, indicating a high level of securities lending [1]. Business Performance - As of June 30, the number of shareholders for Hebang Biotechnology is 200,500, a decrease of 2.35% from the previous period, while the average circulating shares per person increased by 2.41% to 44,043 shares [2]. - For the first half of 2025, Hebang Biotechnology reported an operating income of 3.92 billion yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 51.77 million yuan, down 73.07% year-on-year [2]. Dividend Information - Since its A-share listing, Hebang Biotechnology has distributed a total of 1.205 billion yuan in dividends, with 553 million yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders of Hebang Biotechnology, the Southern CSI 500 ETF ranks as the fifth largest shareholder with 92.27 million shares, an increase of 12.80 million shares compared to the previous period. Conversely, Hong Kong Central Clearing Limited, the sixth largest shareholder, holds 73.19 million shares, a decrease of 50.63 million shares from the previous period [3].

Core Points - The company, Jiangsu Suli Fine Chemical Co., Ltd., disclosed its key operating data for the first half of 2025, including production, sales, and revenue figures for its main products [1] Group 1: Main Products Performance - The sales volume of pesticides and pesticide intermediates reached 23,603.54 tons, generating revenue of 231.88 million yuan, with a production volume of 77,976.20 tons [1] - The sales volume of flame retardants and flame retardant intermediates was not specified in the provided data [1] Group 2: Price Changes of Main Products - The average selling price for pesticides and pesticide intermediates was 3.36 million yuan per ton, showing a decrease of 0.59% compared to the same period last year [1] - The average selling price for flame retardants and flame retardant intermediates was 3.68 million yuan per ton, reflecting an increase of 6.36% year-on-year [1] Group 3: Raw Material Price Changes - The average procurement price for bromine was 1.87 million yuan per ton, with a year-on-year increase of 7.49% [1] - The average procurement price for xylene was 0.84 million yuan per ton, showing a decrease of 2.38% [1] - The average procurement price for liquid ammonia was 0.26 million yuan per ton, down by 19.23% [1] - The average procurement price for benzene was 0.77 million yuan per ton, reflecting a decrease of 20.78% [1]

| 证券代码：603585 | 证券简称：苏利股份 | 公告编号：2025-066 | | --- | --- | --- | | 转债代码：113640 | 转债简称：苏利转债 | | 江苏苏利精细化工股份有限公司 2025 年半年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 主要产品 | 平均售价 | 上年同期 | 变动比率 | | --- | --- | --- | --- | | | （万元/吨） | （万元/吨） | （%） | | 农药及农药中间体 | 3.36 | 3.38 | -0.59 | | 阻燃剂及阻燃剂中间体 | 3.68 | 3.46 | 6.36 | 三、主要原材料的价格变动情况（不含税） | 主要原材料 | 平均采购价 | 上年同期 | 变动比率 | | --- | --- | --- | --- | | | （万元/吨） | （万元/吨） | （%） | | 溴素 | 2.01 | 1.87 | 7.49 | | 间二甲苯 | 0.82 | 0.84 | -2.3 ...